Palivizumab — CAS 216995-50-1

Palivizumab is a humanized monoclonal antibody directed against an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Manufactured by Mediocon Inc at its GMP-certified facility in Maharashtra, India, it is used for prophylaxis of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk.

• Prevention of RSV infections in premature infants and neonates
• Prophylaxis of serious RSV lower respiratory tract disease
• Used in pediatric patients with congenital heart disease
• Management of bronchopulmonary dysplasia in high-risk infants

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support